Extensive reduction in choroidal thickness after photodynamic therapy in eyes with central serous chorioretinopathy

Sci Rep. 2023 Jul 5;13(1):10890. doi: 10.1038/s41598-023-37802-w.

Abstract

We examined the effect of reduced fluence (rf)-photodynamic therapy (PDT) of the macular area on the wide-field choroidal thickness in 20 eyes with central serous chorioretinopathy (CSC) and 20 age- and sex-matched control eyes. The choroidal thickness at the posterior pole was measured before and after rf-PDT, using a grid with inner and outer rings, each divided into superotemporal, inferotemporal, superonasal, and inferonasal quadrants, respectively, making up a total of nine subfields including the central 3 mm ring. Before treatment, all eyes showed wide-field choroidal thickening from the dilated vortex vein ampulla to the fovea, along the course of the vein. After rf-PDT of the macular area, the choroidal thickness significantly decreased, not only in the irradiated macular area but also outside the arcade vessels in all quadrants (p < 0.001 for all inner subfields; p = 0.035 and p = 0.024 for the outer superonasal and inferonasal subfields, respectively; p < 0.001 and p = 0.004 for the outer superotemporal and inferotemporal subfields, respectively). For control eyes, the choroidal thickness did not differ between the initial visit and follow-up 1.2 ± 0.7 months after the initial visit (p > 0.05 for all subfields). These findings provide new insights into the pathogenesis of CSC and explain the reasons for the effectiveness of rf-PDT for this condition.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Central Serous Chorioretinopathy* / drug therapy
  • Central Serous Chorioretinopathy* / pathology
  • Choroid / blood supply
  • Fluorescein Angiography
  • Humans
  • Photochemotherapy*
  • Photosensitizing Agents / therapeutic use
  • Retrospective Studies
  • Tomography, Optical Coherence
  • Verteporfin / therapeutic use

Substances

  • Photosensitizing Agents
  • Verteporfin